Expert board resolution: possibilities of ethiotropic therapy for respiratory infections caused by RNA viruses
- Autores: - -
- Edição: Volume 7, Nº 5 (2021)
- Páginas: 193-195
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288371
- ID: 288371
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Bibliografia
- Gupta A., Madhavan M.V., Sehgal K. et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7): 1017-32. doi: 10.1038/ s41591-020-0968-3.
- Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B. Phys Biol Sci. 2017; 93(7): 449-63. doi: 10.2183/pjab.93.027.
- Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209: 107512. doi: 10.1016/j.pharmthera.2020.107512.
- Chen C., Zhang Y., Huang J. et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial medRxiv. 2020.03.17.20037432 doi: 10.1101/2020.03.17.20037432.
- Cai Q., Yang M., Liu D. et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing). 2020; 6(10): 1192-98. doi: 10.1016/j.eng.2020.03.007.
- Preliminary report of the favipiravir observational study in Japan (2020/5/15). Favipiravir observational study group. Available at: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf (date of access - 11.05.2021).
- Балыкова Л.А., Грановская М.В., Заславская К.Я. с соавт. Новые возможности направленной противовирусной терапии COVID-19: результаты многоцентрового клинического исследования эффективности и безопасности применения препарата Арепливир. Инфекционные болезни: новости, мнения, обучение. 2020; 3: 16-29. doi: https://doi.org/10.33029/2305-3496-2020-9-3-16-29.
- Study of favipiravir compared to standard of care in hospitalized patients with COVID-19, NCT04542694. Available at: https://clinicaltrials.gov/ct2/show/NCT04542694?term=Areplivir&draw=2&rank=1 (date of access - 11.05.2021).
- Зайратьянц О.В., Малявин А.Г., Самсонова М.В. с соавт. Патоморфологические изменения в легких при COVID-19: клинические и терапевтические параллели. Терапия. 2020; 5: 35-46. doi: https://doi.org/10.18565/therapy.2020.5.35-46.
Arquivos suplementares
